Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis

References

• WHO: Ebola virus disease [situation report] Geneva, Switzerland: World Health Organization; 2016http://apps.who.int/ebola/ebola-situation-reports .
   Google Scholar
• Urbanowicz RA, McClure CP, Sakuntabhai A, Sall AA, Kobinger G, Müller MA, Holmes EC, Rey FA, Simon-Loriere E, Ball JK, et al. Human adaptation of Ebola virus during the West African outbreak. Cell. 2016;167:1079–1087.e5. doi:10.1016/j.cell.2016.10.013.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505–18. doi:10.1016/S0140-6736(16)32621-6.
   PubMed Web of Science ®Google Scholar
• Heppner D, Kemp T, Martin B, Ramsey W, Nichols R, Dasen E, Link CJ, Das R, Xu ZJ, Sheldon EA, et al. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;17:854‐866. doi:10.1016/S1473-3099(17)30313-4.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–303. doi:10.1056/NEJMoa1910993.
   PubMed Web of Science ®Google Scholar
• Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines. 2016;15:1101–12. doi:10.1080/14760584.2016.1187566.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Hu Y, Liang Q, Wei M, Zhu F. Ebola vaccines in clinical trial: the promising candidates. Hum Vaccines Immunother. 2017;13:153–68. doi:10.1080/21645515.2016.1225637.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 5.0. 2017 Nov 27.
   Google Scholar
• Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928. doi:10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Schwarzer G, Carpenter JR, Rücker G. Meta-analysis with R. Springer International Publishing; 2015. p. 252.
   Google Scholar
• Martin J, Sullivan N, Enama M, Gordon I, Roederer M, Koup R, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267‐1277. doi:10.1128/CVI.00162-06.
   Google Scholar
• Ledgerwood J, Costner P, Desai N, Holman L, Enama M, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304‐313. doi:10.1016/j.vaccine.2010.10.037.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Hou L-H, Li J-X, Wu S-P, Liu P, Zhang G-R, Hu Y-M, Meng F-Y, Xu -J-J, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015;385:2272–79. doi:10.1016/S0140-6736(15)60553-0.
   PubMed Web of Science ®Google Scholar
• Huttner A, Dayer J, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156‐1166. doi:10.1016/S1473-3099(15)00154-1.
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz N, Millard M, Enama M, Tindikahwa A, Sekiziyivu A, Costner P, Sitar S, Glover D, Hu Z, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet Lond Engl. 2015;385:1545‐1554.
   Google Scholar
• Agnandji S, Huttner A, Zinser M, Njuguna P, Dahlke C, Fernandes J, Yerly S, Dayer J-A, Kraehling V, Kasonta R, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647‐1660. doi:10.1056/NEJMoa1502924.
   PubMed Web of Science ®Google Scholar
• Tapia M, Sow S, Lyke K, Haidara F, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31‐42.
   Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16:311‐320. doi:10.1016/S1473-3099(15)00486-7.
   Web of Science ®Google Scholar
• Milligan I, Gibani M, Sewell R, Clutterbuck E, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016;315:1610‐1623. doi:10.1001/jama.2016.4218.
   PubMed Web of Science ®Google Scholar
• Agnandji S, Fernandes J, Bache E, Obiang Mba R, Brosnahan J, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, et al. Safety and immunogenicity of rVSVDELTAG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: a phase I randomised trial. Plos Med. 2017;14. doi:10.1371/journal.pmed.1002402.
   PubMed Web of Science ®Google Scholar
• Zhu F, Wurie A, Hou L, Liang Q, Li Y, Russell J, Wu SP, Li JX, Hu YM, Guo Q, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2017;389:621‐628.
   Google Scholar
• Kennedy S, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377:1438‐1447. doi:10.1056/NEJMoa1614067.
   PubMed Web of Science ®Google Scholar
• ElSherif M, Brown C, MacKinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ Can Med Assoc J. 2017;189:E819‐E827. doi:10.1503/cmaj.170074.
   PubMed Web of Science ®Google Scholar
• Li J, Hou L, Meng F, Wu S, Hu Y, Liang Q, Chu K, Zhang Z, Xu -J-J, Tang R, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5:e324‐e334. doi:10.1016/S2214-109X(16)30367-9.
   Web of Science ®Google Scholar
• Regules J, Beigel J, Paolino K, Voell J, Castellano A, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376:330‐341. doi:10.1056/NEJMoa1414216.
   PubMed Web of Science ®Google Scholar
• Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, Douoguih M. Safety and Immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J Infect Dis. 2019;220:57‐67. doi:10.1093/infdis/jiz071.
   Web of Science ®Google Scholar
• Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J Infect Dis. 2019;220(1):46‐56. doi:10.1093/infdis/jiz070.
   PubMed Web of Science ®Google Scholar
• Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson MA, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, et al. The Sierra Leone trial to induce a vaccine against Ebola: an evaluation of rVSVΔG-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak. J Infect Dis. 2018;217:S6‐15. doi:10.1093/infdis/jiy020.
   Web of Science ®Google Scholar
• Halperin SA, Arribas JR, Andrews CP, Chu L, Das R, Simon JK, Simon JK, Onorato MT, Liu K, Martin J, et al. Six-month safety data of recombinant vesicular stomatitis virus ebola envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017;215:1789‐98. doi:10.1093/infdis/jix189.
   Web of Science ®Google Scholar
• Halperin SA, Das R, Onorato MT, Lui K, Martin J, Grant-Klein R, Nichols R, Coller B-A, Helmond FA, Simon JK, et al. Immunogenicity, lot consistency, and extended safety of rVSVΔG-ZEBOV-GP vaccine: a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2019;220:1127‐35. doi:10.1093/infdis/jiz241.
   PubMed Web of Science ®Google Scholar
• Clark DK, Xu R, Matassov D, Latham TE, Ota-Setlik A, Gerardi C, Luckay A, Witko SE, Hermida L, Higgins T, et al. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccines: a randomized double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020;20:455‐66.
   Web of Science ®Google Scholar
• Niemuth NA, Rudge TL Jr, Sankovich KA, Anderson MS, Skomrock ND, Badorrek CS, Sabourin CL. Method feasibility for cross-species testing, qualification, and validation of the Filovirus animal nonclinical group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. Plos ONE. 2020;15(10):e0241016. doi:10.1371/journal.pone.0241016.
   PubMed Web of Science ®Google Scholar
• Jüni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analysis of controlled trials: empirical study. Int J Epidemiol. 2002;31:115–23. doi:10.1093/ije/31.1.115.
   PubMed Web of Science ®Google Scholar